Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
ln Vitro |
The migration of HCECs is impacted by LL-37, human TFA (1–20 μg/mL; 24 h) [2]. HCECs' production of cytokines is influenced by LL-37, human TFA (0.0001–5 μg/mL; 6–24 h) [2]. When applied to HCECs at concentrations more than 10 μg/mL, LL-37, human TFA (1-100 μg/mL; 24 h), demonstrates dose-dependent cytotoxicity[2].
|
---|---|
ln Vivo |
Mice with pneumonia caused by MRSA are treated better with LL-37, human TFA (0.4-2.0 mg/kg; intratracheal injection once) [3].
|
Cell Assay |
Cell Migration Assay [2]
Cell Types: Human corneal epithelial cell(HCEC) Tested Concentrations: 1, 2.5, 5, 10 and 20 μg/mL Incubation Duration: 24 hrs (hours) Experimental Results: Dose-dependently stimulated HCECs migration but demonstrated no effect on cell proliferation. Cell Viability Assay[2] Cell Types: Human corneal epithelial cell(HCEC) Tested Concentrations: 0.0001, 0.001, 0.01, 0.1, 0.5, 1, and 5 μg/mL Incubation Duration: 6 and 24 hrs (hours) Experimental Results: Dose-dependently increased IL -8, IL-6, IL-1β and TNF-α secretion at 6 and 24 hrs (hours) in HCECs. |
Animal Protocol |
Animal/Disease Models: 6-8 week-old C57BL/6 mice with MRSA-induced pneumonia[3]
Doses: 0.4, 0.8, 1.2, 1.6 and 2.0 mg/kg Route of Administration: Intracheal injection; 0.4-2.0 mg/kg once Experimental Results: diminished IL-6 and TNF-α release to attenuated MRSA-induced pneumonia of testing mice. |
References |
[1]. Dürr UH, et al. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta. 2006 Sep;1758(9):1408-25.
[2]. Huang LC, et al. Multifunctional roles of human cathelicidin (LL-37) at the ocular surface. Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2369-80. [3]. Hou M, et al. Antimicrobial peptide LL-37 and IDR-1 ameliorate MRSA pneumonia in vivo. Cell Physiol Biochem. 2013;32(3):614-23. |
Molecular Formula |
C205H340N60O53.XC2HF3O2
|
---|---|
Molecular Weight |
4493.26 (free base)
|
Related CAS # |
LL-37, human;154947-66-7;LL-37, human acetate
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O :~100 mg/mL
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 16.67 mg/mL (Infinity mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.